DBCO-PEG4-Val-Cit-PAB-MMAF

Cat. No.:	HY-130990
CAS No.:	2244602-23-9
Molecular Formula:	$C_{88}H_{126}N_{12}O_{20}$
Molecular Weight:	1672.01
Target:	Drug-Linker Conjugates for ADC
Pathway:	Antibody-drug Conjugate/ADC Related
Storage:	-20°C, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 250 mg/mL (149.52 mM; Need ultrasonic)

Preparing Stock Solutions

Concentration \ Solvent \ Mass	1 mg	5 mg	10 mg
1 mM	0.5981 mL	2.9904 mL	5.9808 mL
5 mM	0.1196 mL	0.5981 mL	1.1962 mL
10 mM	0.0598 mL	0.2990 mL	0.5981 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: 6.25 mg/mL (3.74 mM); Suspended solution; Need ultrasonic
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: 6.25 mg/mL (3.74 mM); Suspended solution; Need ultrasonic
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 6.25 mg/mL (3.74 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

DBCO-PEG4-Val-Cit-PAB-MMAF consists a cleavable 4 unit PEG ADC linker (DBCO-PEG4-Val-Cit-PAB) and a potent tubulin polymerization inhibitor (MMAF). DBCO-PEG4-Val-Cit-PAB-MMAF can be used in the synthesis of antibody-drug conjugates (ADCs)[1].

IC_{50} & Target

Auristatin

In Vitro

ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA